Supply Chain Intelligence

Mereo BioPharma Group plc Supply Chain

MREO supply chain intelligence for Mereo BioPharma Group plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

MREO ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

2Suppliers
4Customers
2Debt Items
20Related Chains

Mereo BioPharma Group plc Suppliers

TickerNameConfidenceEvidence
ULTRAGENYX ULTRAGENYX 92% In December 2024, we entered into a manufacturing and supply agreement with Ultragenyx (the “Ultragenyx Manufacturing and Supply Agreement”) under which Ultragenyx is responsible for the manufacture …
ASTRAZENECA-AB ASTRAZENECA-AB 90% In October 2017, we entered into an exclusive license and option agreement ("the AstraZeneca License Agreement") and subscription deed (the "AstraZeneca Subscription Deed"), together (the "Original A…

Mereo BioPharma Group plc Customers

TickerNameConfidenceEvidence
AZN AstraZeneca PLC 70% under various agreements with Novartis and AstraZeneca, we have agreed to make milestone payments and pay royalties on potential future commercial sales
AZN AstraZeneca PLC 70% Reciprocal relationship from AZN graph: Reciprocal relationship from MREO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MREO graph: under various agreements with Novarti…
NVS Novartis AG 70% under various agreements with Novartis and AstraZeneca, we have agreed to make milestone payments and pay royalties on potential future commercial sales
NVS Novartis AG 70% Reciprocal relationship from NVS graph: Reciprocal relationship from MREO graph: under various agreements with Novartis and AstraZeneca, we have agreed to make milestone payments and pay royalties on…

Mereo BioPharma Group plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
MREO-DEBT-11065 Warrants outstanding: 1551699 90% xbrl warrant detail from xbrl 2025-12-31.
MREO-DEBT-11066 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.

Mereo BioPharma Group plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Mereo BioPharma Group plc.

Mereo BioPharma Group plc Ownership

HolderNameConfidenceEvidence
MREO-OWNER-RUBRIC-CAPITAL-MANAGEMENT-LP Rubric Capital Management LP 90% 13F overlay lists Rubric Capital Management LP as top holder; 67 tracked holders.

Mereo BioPharma Group plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CCCC C4 Therapeutics, Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
DEO Diageo plc 100.00 2
BNBX BNB Plus Corp. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
View MREO supply chain intel →

Explore the full interactive supply chain map for Mereo BioPharma Group plc.

Open MREO supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map